Clinical features and latency interval from first other malignancy to MF
| Characteristic . | Patients, N (%) . | Prior malignancies, N* . | Latency time (range), y . | Prior malignancy not in CR at MF diagnosis, N . | CHT, XRT, and CMT for first OM, N† . |
|---|---|---|---|---|---|
| All patients | 121 | 151 | 7.6 (0.3-44) | 6 | CHT 16, XRT 17, CMT 9 |
| Men | 76 (63) | 100 | 7 (0.3-29) | 2 | CHT 7, XRT 13, CMT 5 |
| Women | 45 (37) | 51 | 9.5 (0.5-44) | 1 | CHT 9, XRT 4, CMT 4 |
| Age at MF diagnosis, y | |||||
| >65 | 89 (74) | 110 | 8 (0.3-38) | 1 | CHT 11, XRT 15, CMT 3 |
| <65 | 32 (26) | 41 | 7 (1-44) | 2 | CHT 5, XRT 2, CMT 6 |
| Primary therapy approach to OM | |||||
| SX only/OBS | 79 (65) | 121 | 7 (0.2-38) | 1 | 0 |
| XRT | 17 (14) | 18 | 6 (2-44) | 2 | All XRT |
| CHT/CMT | 25 (21) | 37 | 7 (1-12) | 3 | CHT 16, CMT 9 |
| Age at OM diagnosis, y‡ | |||||
| <34 | 6 (5) | 6 | 21 (3-44) | 0 | CHT 2, XRT 1, CMT 2 |
| 35-49 | 18 (15) | 20 | 19 (2-38) | 0 | CHT 2, XRT 2, CMT 3 |
| 50-64 | 50 (41) | 57 | 9 (1-25) | 2 | CHT 7, XRT 4, CMT 2 |
| >65 | 43 (36) | 68 | 4 (0.4-15) | 4 | CHT 5, XRT 10, CMT 2 |
| OM types | |||||
| Testes | 1 | 30 | — | ||
| Cervix | 2 | 21 (11-32) | — | XRT 1 | |
| Bladder | 7 | 11 (7-17) | — | ||
| Pancreas | 1 | 11 | — | CHT 1 | |
| Colorectal | 12 | 15 | 10.5 (3-26) | — | CHT 2, CMT 1 |
| Breast | 12 | 10 (0.5-38) | 1 | CHT 3, XRT 1, CMT 1 | |
| Multiple myeloma | 1 | 10 | 1 | CHT 1 | |
| Ovary | 3 | 10 (3-37) | — | CHT 2 | |
| Melanoma | 20 | 26 | 8 (0.8-24) | — | |
| Thyroid | 5 | 8 (1-44) | — | XRT 2 | |
| Leukemia | 6 | 8 (1-16) | 1 | CHT 4 | |
| Lung | 1 | 7.5 | — | ||
| Lymphoma | 8 | 7 (2.5-18) | 2 | CHT 3, CMT 3 | |
| Prostate | 45 | 6 (0.3-25) | 2 | XRT 10, CMT 3§ | |
| Renal cell | 8 | 3.5 (1.2-22) | — | CHT 1 | |
| Vulva | 2 | 3 (2-7) | — | CMT 1 | |
| Endometrium | 3 | 3 (1-15) | — | XRT 1 | |
| Sarcomatoid squamous cell carcinoma, LN+ | 2 | 3 | — | XRT 2 | |
| Sarcoma | 3 | 3 (1-4) | — | ||
| CNS malignancy | 2 | 2 (1-3) | — |
| Characteristic . | Patients, N (%) . | Prior malignancies, N* . | Latency time (range), y . | Prior malignancy not in CR at MF diagnosis, N . | CHT, XRT, and CMT for first OM, N† . |
|---|---|---|---|---|---|
| All patients | 121 | 151 | 7.6 (0.3-44) | 6 | CHT 16, XRT 17, CMT 9 |
| Men | 76 (63) | 100 | 7 (0.3-29) | 2 | CHT 7, XRT 13, CMT 5 |
| Women | 45 (37) | 51 | 9.5 (0.5-44) | 1 | CHT 9, XRT 4, CMT 4 |
| Age at MF diagnosis, y | |||||
| >65 | 89 (74) | 110 | 8 (0.3-38) | 1 | CHT 11, XRT 15, CMT 3 |
| <65 | 32 (26) | 41 | 7 (1-44) | 2 | CHT 5, XRT 2, CMT 6 |
| Primary therapy approach to OM | |||||
| SX only/OBS | 79 (65) | 121 | 7 (0.2-38) | 1 | 0 |
| XRT | 17 (14) | 18 | 6 (2-44) | 2 | All XRT |
| CHT/CMT | 25 (21) | 37 | 7 (1-12) | 3 | CHT 16, CMT 9 |
| Age at OM diagnosis, y‡ | |||||
| <34 | 6 (5) | 6 | 21 (3-44) | 0 | CHT 2, XRT 1, CMT 2 |
| 35-49 | 18 (15) | 20 | 19 (2-38) | 0 | CHT 2, XRT 2, CMT 3 |
| 50-64 | 50 (41) | 57 | 9 (1-25) | 2 | CHT 7, XRT 4, CMT 2 |
| >65 | 43 (36) | 68 | 4 (0.4-15) | 4 | CHT 5, XRT 10, CMT 2 |
| OM types | |||||
| Testes | 1 | 30 | — | ||
| Cervix | 2 | 21 (11-32) | — | XRT 1 | |
| Bladder | 7 | 11 (7-17) | — | ||
| Pancreas | 1 | 11 | — | CHT 1 | |
| Colorectal | 12 | 15 | 10.5 (3-26) | — | CHT 2, CMT 1 |
| Breast | 12 | 10 (0.5-38) | 1 | CHT 3, XRT 1, CMT 1 | |
| Multiple myeloma | 1 | 10 | 1 | CHT 1 | |
| Ovary | 3 | 10 (3-37) | — | CHT 2 | |
| Melanoma | 20 | 26 | 8 (0.8-24) | — | |
| Thyroid | 5 | 8 (1-44) | — | XRT 2 | |
| Leukemia | 6 | 8 (1-16) | 1 | CHT 4 | |
| Lung | 1 | 7.5 | — | ||
| Lymphoma | 8 | 7 (2.5-18) | 2 | CHT 3, CMT 3 | |
| Prostate | 45 | 6 (0.3-25) | 2 | XRT 10, CMT 3§ | |
| Renal cell | 8 | 3.5 (1.2-22) | — | CHT 1 | |
| Vulva | 2 | 3 (2-7) | — | CMT 1 | |
| Endometrium | 3 | 3 (1-15) | — | XRT 1 | |
| Sarcomatoid squamous cell carcinoma, LN+ | 2 | 3 | — | XRT 2 | |
| Sarcoma | 3 | 3 (1-4) | — | ||
| CNS malignancy | 2 | 2 (1-3) | — |
—, Unknown; CMT, combined modality treatment; CNS, central nervous system; CR, complete remission; ET, essential thrombocythemia; LN, lymph node positive; OBS, observation; OM, other malignancy; PV, polycythemia vera.
Number of prior malignancies is only shown if it differs from the total number of patients; 23 patients had >1 primary prior malignancy.
The last column shows CHT, radiation, or combined modality regimen used for first prior malignancy; conservative approach and SX only are not stated.
Age at the time of prior malignancy diagnosis was not known in 4 patients; 28 patients had OM after ET/PV preceding MF, 13 of them (46%) were treated with cytoreductive therapy with either hydroxyurea (n = 12) or interferon α (n = 1), and only 2 patients previously treated with hydroxyurea later developed OM (1 patient breast carcinoma and the other B-cell non-Hodgkin lymphoma).
Three patients had sequential CMT representing a combination of XRT for prostate carcinoma and CHT for a second primary (not counted above separately for the second OM): bladder carcinoma, non-Hodgkin lymphoma, and sarcoma.